Cobimetinib

The medication produced by Lucius Pharmaceuticals has demonstrated good efficacy and safety, providing patients with relevant conditions a treatment option of clinical value.

The following is an overview of key information for cobimetinib.

Active Ingredient

The main active ingredient is cobimetinib fumarate.

Target Population

It is indicated for adult patients with melanoma harboring BRAF V600E/V600K mutations, as well as adult patients with histiocytic neoplasms.

Dosage and Administration

The recommended dose is 60 mg taken orally once daily. Administer continuously for 21 days followed by a 7-day drug-free period, forming a 28-day cycle.

Use in Special Populations

It is contraindicated in pregnant women.

Lactating women should discontinue breastfeeding during treatment.

Patients of childbearing age must use effective contraceptive measures.

Overdose

Currently, there is no relevant information available regarding overdose of this medication.

Storage

Store at room temperature below 30°C.

Pharmacokinetics

After oral administration, the drug reaches peak concentration in approximately 2.4 hours, with a mean elimination half-life of 44 hours. It is mainly excreted via feces.

FDA，2023.05